vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and MOGU Inc. (MOGU). Click either name above to swap in a different company.
GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $19.5M, roughly 1.9× MOGU Inc.). GYRE THERAPEUTICS, INC. runs the higher net margin — -3.7% vs -44.3%, a 40.6% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs -12.4%). GYRE THERAPEUTICS, INC. produced more free cash flow last quarter ($-5.8M vs $-10.7M).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
Mogu Mogu is a brand of fruit-flavoured drink with pieces of nata de coco, produced by Thailand-based Sappe Public Company Limited and exported to many international markets, especially South Korea, the Philippines, Indonesia and France.
GYRE vs MOGU — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $19.5M |
| Net Profit | $-1.4M | $-8.6M |
| Gross Margin | 95.3% | 0.0% |
| Operating Margin | 0.3% | -71.6% |
| Net Margin | -3.7% | -44.3% |
| Revenue YoY | 33.4% | -12.4% |
| Net Profit YoY | -340.1% | -5.0% |
| EPS (diluted) | $-0.01 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.2M | — | ||
| Q3 25 | $30.6M | — | ||
| Q2 25 | $26.8M | — | ||
| Q1 25 | $22.1M | $19.5M | ||
| Q4 24 | $27.9M | — | ||
| Q3 24 | $25.5M | — | ||
| Q2 24 | $25.2M | — | ||
| Q1 24 | $27.2M | $22.2M |
| Q4 25 | $-1.4M | — | ||
| Q3 25 | $5.9M | — | ||
| Q2 25 | $1.6M | — | ||
| Q1 25 | $3.7M | $-8.6M | ||
| Q4 24 | $569.0K | — | ||
| Q3 24 | $2.9M | — | ||
| Q2 24 | $4.5M | — | ||
| Q1 24 | $9.9M | $-8.2M |
| Q4 25 | 95.3% | — | ||
| Q3 25 | 94.7% | — | ||
| Q2 25 | 95.7% | — | ||
| Q1 25 | 95.9% | 0.0% | ||
| Q4 24 | 95.8% | — | ||
| Q3 24 | 96.2% | — | ||
| Q2 24 | 96.9% | — | ||
| Q1 24 | 96.4% | 0.0% |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 22.7% | — | ||
| Q2 25 | 8.1% | — | ||
| Q1 25 | 10.3% | -71.6% | ||
| Q4 24 | 2.4% | — | ||
| Q3 24 | 16.6% | — | ||
| Q2 24 | 12.7% | — | ||
| Q1 24 | 29.7% | -49.4% |
| Q4 25 | -3.7% | — | ||
| Q3 25 | 19.4% | — | ||
| Q2 25 | 5.9% | — | ||
| Q1 25 | 16.9% | -44.3% | ||
| Q4 24 | 2.0% | — | ||
| Q3 24 | 11.2% | — | ||
| Q2 24 | 18.0% | — | ||
| Q1 24 | 36.6% | -37.0% |
| Q4 25 | $-0.01 | — | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $0.00 | — | ||
| Q1 25 | $0.00 | $0.00 | ||
| Q4 24 | $0.00 | — | ||
| Q3 24 | $0.01 | — | ||
| Q2 24 | $0.01 | — | ||
| Q1 24 | $0.03 | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | $52.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $106.0M | $70.1M |
| Total Assets | $166.1M | $118.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | — | ||
| Q3 25 | $60.0M | — | ||
| Q2 25 | $54.4M | — | ||
| Q1 25 | $29.9M | $52.3M | ||
| Q4 24 | $26.7M | — | ||
| Q3 24 | $25.1M | — | ||
| Q2 24 | $25.1M | — | ||
| Q1 24 | $37.4M | $58.2M |
| Q4 25 | $106.0M | — | ||
| Q3 25 | $101.9M | — | ||
| Q2 25 | $92.0M | — | ||
| Q1 25 | $68.1M | $70.1M | ||
| Q4 24 | $63.3M | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | $60.4M | — | ||
| Q1 24 | $56.6M | $81.5M |
| Q4 25 | $166.1M | — | ||
| Q3 25 | $159.4M | — | ||
| Q2 25 | $152.6M | — | ||
| Q1 25 | $129.8M | $118.3M | ||
| Q4 24 | $125.4M | — | ||
| Q3 24 | $125.2M | — | ||
| Q2 24 | $120.9M | — | ||
| Q1 24 | $122.0M | $130.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $-9.4M |
| Free Cash FlowOCF − Capex | $-5.8M | $-10.7M |
| FCF MarginFCF / Revenue | -15.5% | -55.2% |
| Capex IntensityCapex / Revenue | 0.4% | 7.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | — | ||
| Q3 25 | $4.7M | — | ||
| Q2 25 | $2.1M | — | ||
| Q1 25 | $-129.0K | $-9.4M | ||
| Q4 24 | $-2.8M | — | ||
| Q3 24 | $1.7M | — | ||
| Q2 24 | $-5.5M | — | ||
| Q1 24 | $2.9M | $-5.6M |
| Q4 25 | $-5.8M | — | ||
| Q3 25 | $4.0M | — | ||
| Q2 25 | $1.8M | — | ||
| Q1 25 | $-251.0K | $-10.7M | ||
| Q4 24 | $-2.8M | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $-6.9M | — | ||
| Q1 24 | $2.7M | $-18.6M |
| Q4 25 | -15.5% | — | ||
| Q3 25 | 13.1% | — | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | -1.1% | -55.2% | ||
| Q4 24 | -10.1% | — | ||
| Q3 24 | 4.1% | — | ||
| Q2 24 | -27.5% | — | ||
| Q1 24 | 9.8% | -84.0% |
| Q4 25 | 0.4% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 0.6% | 7.1% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 5.8% | — | ||
| Q1 24 | 0.9% | 58.7% |
| Q4 25 | — | — | ||
| Q3 25 | 0.79× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | -0.03× | — | ||
| Q4 24 | -4.85× | — | ||
| Q3 24 | 0.60× | — | ||
| Q2 24 | -1.21× | — | ||
| Q1 24 | 0.29× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
